GlassScriptPhysician profile
Hanh M Ho
NPI 1912584236
$1,712.14
in general payments reported to CMS, 2019-2025
13 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $242 · 2024: $295 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $311.09 | 2024-2025 | Fasenra, Tezspire |
| Organon LLC | $241.84 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $214.28 | 2024-2025 | Dupixent |
| Biocryst Pharmaceuticals, INC. | $157.48 | 2025 | Orladeyo |
| Incyte Corporation | $135.52 | 2025 | Opzelura, Opzelura |
| Genzyme Corporation | $124.83 | 2024-2025 | |
| Ionis Pharmaceuticals, INC. | $118.53 | 2025 | |
| Csl Behring | $105.90 | 2024-2025 | Andembry, Hizentra |
| Ars Pharmaceuticals Operations, INC. | $101.89 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $94.45 | 2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $49.82 | 2024-2025 | Takhzyro, Hyqvia |
| Grifols USA, LLC | $31.26 | 2025 | Xembify |
| Genentech USA, INC. | $25.25 | 2025 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanh Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.